Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow-derived mesenchymal stem cells (Amy Lightner)
- Development stage
- Unknown
- Lead developer
- Cleveland Clinic
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intralesional
01
Overview
Allogeneic bone marrow-derived mesenchymal stem cells (MSCs) are a cellular therapy being investigated for the treatment of refractory perianal fistulizing Crohn's disease, particularly in pediatric and adolescent populations. Developed under the leadership of Dr. Amy Lightner at the Cleveland Clinic, this therapy involves the direct injection of 75 million adult donor-derived MSCs into the fistula tracts. The mechanism of action relies on the innate immunomodulatory properties of MSCs, which secrete a variety of anti-inflammatory cytokines and growth factors (paracrine signaling) to suppress local inflammation and promote tissue regeneration and fistula closure. Unlike autologous therapies, these allogeneic cells are "off-the-shelf," derived from healthy adult bone marrow, and do not require a prior harvest from the patient.
- Other names
- allogeneic bone marrow-derived mesenchymal stem cellsbone marrow-derived MSCsadult allogeneic bone marrow derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic bone marrow-derived mesenchymal stem cells (Amy Lightner).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow-derived mesenchymal stem cells (Amy Lightner).